Search results for: d842V

/Search: d842V
1 02, 2011

D842V Gets Its Moment in the Spotlight

By |2018-06-12T11:11:01-04:00February 1st, 2011|D842V, News, Patient Registry|

The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.

6 01, 2011

New Treatments of D842V Mutations

By |2019-04-03T12:02:19-04:00January 6th, 2011|Clinical Trials, D842V, Diagnosis, Mutational Testing, Mutations, News, Research|

 UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]

20 12, 2007

References – PDGFRA and D842V

By |2014-09-03T13:23:03-04:00December 20th, 2007|D842V, Mutations, Research|

1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin [...]

17 12, 2018

An Exciting Time for GIST Research

By |2019-01-02T14:49:47-04:00December 17th, 2018|Conferences, Newsletter, Research|

Left to right: Laura Occhiuzzi, Pete Knox, Alyssa O’Driscoll, Sarcoma Alliance, Annie Achee, National LeioMyoSarcoma Foundation, Denise Reinke, SARC, and Mitch Achee, National LeioMyoSarcoma Foundation. GIST Research from CTOS 2018 A web-based [...]

29 06, 2018

New Technology Developed Which Can Predict GIST Patient’s Response to Drugs with Amazing Accuracy

By |2018-10-29T13:42:22-04:00June 29th, 2018|GIST Education, Mutational Testing, News, Newsletter|

Researchers have developed a test that can accurately identify over 20% of GIST patients that are unlikely to respond to currently approved treatments. In addition, it can identify which patients need a higher dose [...]

Need a new search?

If you didn't find what you were looking for, try a new search!

Recent Posts

Upcoming Events

  1. LRG Canada Logo
  2. GDOL Portland 2019

    GDOL Portland 2019

    June 22 @ 8:30 AM - 6:00 PM
  3. Life Fest 2020 New Orleans

    Life Fest New Orleans

    July 10, 2020 - July 12, 2020